Literature DB >> 26773773

Combined treatment with low dose prednisone and escin improves the anti-arthritic effect in experimental arthritis.

Yuan Du1, Yanqin Song1, Leiming Zhang1, Menglin Zhang1, Fenghua Fu2.   

Abstract

The present study was aimed at investigating whether low dose oral prednisone combined with escin could inhibit the progression of adjuvant-induced arthritis (AIA) in rats. Adjuvant arthritis was induced in SD rats began day 1 for 28 days. Prednisone at doses of 2, 10 mg/kg/day alone or escin at doses of 5, 10 mg/kg/day alone, or prednisone at dose of 2 mg/kg/day with escin at doses of 5 or 10 mg/kg/day were given to different groups of rats intragastrically from day 13 to 28 respectively. Paw swelling, arthritic index, histological and radiographic changes were assessed to evaluate the anti-arthritic effect. Weight growth, spleen and thymus indexes were also calculated. Serum samples were collected for estimation of pro-inflammatory cytokines. Rats developed erosive arthritis of the hind paw when immunized with adjuvant. Prednisone 2 mg/kg combined with escin 5 or 10 mg/kg significantly inhibited the paw swelling. Histopathological and radiographic analysis showed a marked decrease of synovial inflammatory infiltration, synovial hyperplasia and bone erosion by combination therapy, which also markedly suppressed the expression of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6). No significant changes were found in monotherapy group except prednisone 10 mg/kg group. Furthermore, combined treatment rescued some of GCs' adverse effects evidenced by increase in body weight and decrease in index of spleen compared with untreated AIA rats. In conclusion, the combination therapy possessed synergistic anti-arthritic efficacy and reduced adverse effect, which may play a role in the management of human RA.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adjuvant arthritis; Combined treatment; Escin; Inflammatory cytokine; Low dose prednisone; Synergistic effect

Mesh:

Substances:

Year:  2016        PMID: 26773773     DOI: 10.1016/j.intimp.2016.01.006

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  4 in total

1.  Evaluation of the effect of polyphenol of escin compared with ibuprofen and dexamethasone in synoviocyte model for osteoarthritis: an in vitro study.

Authors:  Hossein Maghsoudi; Jamal Hallajzadeh; Mozhghan Rezaeipour
Journal:  Clin Rheumatol       Date:  2018-04-16       Impact factor: 2.980

2.  Aescin Protects against Experimental Benign Prostatic Hyperplasia and Preserves Prostate Histomorphology in Rats via Suppression of Inflammatory Cytokines and COX-2.

Authors:  Mohamed Raafat; Amr A Kamel; Alaa H Shehata; Al-Shaimaa F Ahmed; Asmaa M A Bayoumi; Rabab A Moussa; Mohammed A S Abourehab; Mahmoud El-Daly
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-22

Review 3.  The Use of Herbal Medicines for the Prevention of Glucocorticoid-Induced Osteoporosis.

Authors:  Leiming Zhang; Xiaoli Li; Tianhao Ying; Tian Wang; Fenghua Fu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-12       Impact factor: 5.555

Review 4.  The Biosurfactant β-Aescin: A Review on the Physico-Chemical Properties and Its Interaction with Lipid Model Membranes and Langmuir Monolayers.

Authors:  Ramsia Geisler; Carina Dargel; Thomas Hellweg
Journal:  Molecules       Date:  2019-12-27       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.